Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Squamous cell carcinoma (SCC) of head and neck (SCCHN), including all pharynx, larynx, oral cavity, skin and para-nasal sinus sites. Patients with SCC of unknown primary presenting in the neck clinically compatible with head and neck mucosal primary sites are eligible.~* If prior chemoradiation, radiation, and/or surgery in the potentially curative setting, \> 3 months has elapsed since the end of the potentially curative treatment ended~* If history of other malignancies treated curatively \> 1 year prior to enrollment, no evidence of relapse at the time of enrollment~* If brain metastasis, central nervous system (CNS) imaging documents no evidence of CNS progression at least 30 days following definitive CNS treatment (resection or radiation)~* ≥ 16 years old~* Eastern cooperative oncology group (ECOG) Performance Status \< 3~* Laboratory value requirements at enrollment:~* Absolute neutrophil count \> 1500/mm³~* Platelet count \> 100,000/mm³~* Hemoglobin \> 8 g/dL~* Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) \< 2.5 x upper limit of normal (ULN) unless liver metastases documented. If so, AST and ALT \< 5 x ULN required.~* Total bilirubin \< 1.5 x ULN, EXCEPT if Gilbert's syndrome is present. If so, total bilirubin \< 2.5 x ULN~* Serum Creatinine \< 1.5 mg/dL OR an estimated creatinine clearance from 24 hour urine collection \> 50 mL/min~* Peripheral neuropathy \< grade 2~* Hearing loss in best ear \< grade 2 per Chang criteria if audiogram performed. Formal audiology is not required in patients with no clinical evidence of hearing loss at baseline.~* Ability to understand and the willingness to sign a written informed consent document.~EXCLUSION CRITERIA~* Prior palliative chemotherapy~* Active infections including HIV (EXCEPTION: HIV-positive patients on HAART with undetectable blood HIV levels, or with history or serological evidence of exposure to Hepatitis B without active infection are eligible)~* Prior grade 3 allergic or infusion reactions to docetaxel, cisplatin or cetuximab (EXCEPTION: a history of infusion reactions that were well-tolerated, at physician's discretion)~* Pregnant and/or lactating

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin + Docetaxel + Cetuximab (Type: EXPERIMENTAL): Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.

Based on this trial design, predict the completion outcome and termination type (if applicable).